Phase II Study of Induction Chemoimmunotherapy Followed by Radiotherapy and Organ Preservation in Resectable ESCC

NCT07711470 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

140

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Squamous Cell Carcinoma (ESCC)

Interventions

DRUG: Sugemalimab and Chemotherapy
DRUG: Nab-paclitaxel
DRUG: Cisplatin
RADIATION: Radiation Therapy

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences